New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents

BayerWith approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions. "We need dedicated and creative young scientists if we are to successfully shape the future. That's why with the Bayer Fellowship Program we are helping talented young people to participate in special projects abroad," says Kemal Malik, Bayer Management Board member responsible for Innovation.

Today's "Bayer Fellowship program" follows the tradition of the first company scholarships initiated back in 1923 by Dr. Carl Duisberg, at that time Managing Director of the Bayer Group. Duisberg is regarded as a pioneer in the intensive cooperation between industry and universities, as well as in corporate social responsibility. Explains Dr. Carl-Heinz Duisberg, member of the Scientific Committee of the Bayer Fellowship Program and youngest grandchild of the program's founder: "My grandfather wanted to provide the best development opportunities for young talents because he saw this as a means of ensuring long-term benefits for society. He is also quoted as saying 'We must spend every spare penny on science - it is the best investment we can make.'"

All scholarships underline the mission of the Bayer foundation to work with young people and the next generation of scientists and opinion-leaders and to strengthen interest in the major challenges facing our society, such as health and agriculture.

Alongside the Otto Bayer, Jozef Schell and Carl Duisberg scholarships, the Bayer Fellowship Program also includes the Kurt Hansen and Hermann Strenger scholarships. For the third time, the Bayer Science & Education Foundation offers an additional special budget for "Talents for Africa". The scholarships are targeted at students and vocational trainees in natural science and medical disciplines who would like to realize a particular foreign study project and require financial support for this. In addition to Germany-based applicants who would like to study abroad, the foundation supports scholarship recipients from outside of Germany who wish to realize a comparable project in Germany.

Academic disciplines receiving support this year include the life sciences, chemistry, agriculture as well as human and veterinary medicine, with a total of 56 scholarships being awarded. Three Kurt Hansen scholarship recipients are also receiving assistance for teacher training in the natural sciences. The scholarships in the academic sector are being supplemented by Hermann Strenger scholarships to support young people looking to gain initial work experience abroad as part of a non-academic training program. This year, six young people from Germany are being supported who are planning a period abroad as part of their commercial, technical or health profession training.

Thanks to the Bayer scholarships, 47 new fellows from Germany will start their projects in 18 different countries: Argentina, Australia, Brazil, Chile, Ethiopia, France, Gabon, Israel, Mexico, Nicaragua, Russian Federation, Rwanda, Spain, Sri Lanka, Sweden, Switzerland, United Kingdom and the United States. Another 18 new scholarship winners will be able to implement their individual projects in Germany, coming from: Austria, Bangladesh, Brazil, Canada, Egypt, Finland, Italy, Mexico, Morocco, Netherlands, Nigeria, Pakistan, Russian Federation, Singapore, Syria, Tunisia, Turkey and United Kingdom.

The Bayer Science & Education Foundation thus is launching the eleventh round of its funding program, which offers targeted support for scientific exchange and international work experience for young people. It targets creative, highly motivated and socially committed young people with above-average grades.

The next round of applications starts in June 2018.

More information is available on the Internet at www.bayer-foundations.com.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...